glp-1 dementia news Research shows treatments like Semaglutide & tirzepatide (GLP1) can reduce risk of dementia/Alzheimer’s. , People still argue with the research but how do you argue with data and statistics. Objective GLP-1 drugs failed to slow

Wegovy approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis

Our own natural GLP-1 is broken down within one to two minutes

Tirzepatide (weekly injectable) Dosing frequency: Once weekly, same day each week Half-life: approximately 5 days (120 hours) Peak concentration: 8 to 72 hours after injection Recommended timing approach: The shorter half-life compared to semaglutide means the end-of-week trough is more noticeable

So even though there were steps that employees had to take, it was usually denied the first time and they had to go through an appeal process